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Protective effects of FTY720 on chronic allograft nephropa-
thy by reducing late lymphocytic infiltration.
Background. Lymphocytic infiltration is obvious throughout
early and late stages of chronic allograft nephropathy. Early
infiltrating lymphocytes are involved in initial insults to kid-
ney allografts, but the contribution of late infiltration to long-
term allograft attrition is still controversial. Early application of
FTY720 reduced the number of graft infiltrating lymphocytes,
and inhibited acute rejection. The present study investigated
the potential of FTY720 to reduce the number of infiltrating
lymphocytes even at a late stage, and, thus, slow the pace of
chronic allograft nephropathy.
Methods. Fisher (F344) rat kidneys were orthotopically trans-
planted into Lewis recipients with an initial 10-day course of
cyclosporine A (1.5 mg/kg/day). FTY720, at a dose of 0.5 mg/
kg/day, or vehicle was administered to recipients either from
weeks 12 to 24 or from 20 to 24 after transplantation. Animals
were harvested 24 weeks after transplantation for histologic,
immunohistologic, and molecular analysis.
Results. FTY720, either initiated at 12 or 20 weeks after
transplantation, reduced urinary protein excretion, and sig-
nificantly ameliorated glomerulosclerosis, interstitial fibrosis,
tubular atrophy, and intimal proliferation of graft arteries at
24 weeks after transplantation. Furthermore FTY720 markedly
suppressed lymphocyte infiltration and decreased mRNA lev-
els of interleukin-10 (IL-10), transforming growth factor-b
(TGF-b), and platelet-derived growth factor-B (PDGF-B) but
enhanced the number of apoptotic cells in grafts.
Conclusions. FTY720 ameliorated chronic allograft
nephropathy even at advanced stages. Furthermore, our data
suggest that this effect was achieved by a reduction of graft-
infiltrating lymphocytes.
Thanks to substantial improvements in short-term out-
come, kidney transplantation has become the treatment
of choice for most patients with end-stage renal dis-
eases (ESRD). However, the rate of long-term graft
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failure due to chronic allograft nephropathy remained
at 50% to 80%. [1]. Alloantigen-dependent as well as
nonalloantigen-dependent factors are involved in the de-
velopment of the process. Most of these factors induce the
recruitment of lymphocytes into the grafts [2, 3]. Clin-
ically, biopsies of renal allografts have demonstrated a
predominance of T lymphocytes, not only in grafts un-
dergoing acute but also chronic allograft nephropathy
(35 ± 10% of area infiltrate) [4, 5]. Similarly, in a well-
established rat model of chronic allograft nephropathy,
lymphocyte infiltration patterns in allografts remained
stable throughout different periods after transplantation,
and were consistently more substantial than those noted
in isografts [6, 7].
Lymphocytes infiltrating graft tissue early after trans-
plantation, in concert with the cytokines they release, con-
tribute to early insults to renal allografts, and may result
in acute rejection or predispose for chronic allograft dete-
rioration [8, 9]. However, it remained controversial over
the past decade whether lymphocytic infiltration late after
transplantation plays an essential role. Some studies have
indicated that in chronic allograft nephropathy lympho-
cytes are important mediators of a persistent alloantigen
dependent immune response [10, 11] and the develop-
ment of arteriosclerosis during the ongoing process of
chronic allograft nephropathy [12, 13]. However, others
argue that late lymphocytic infiltration may serve only as
an adjunct of chronic rejection, and the simple presence
of T cells during this period does not necessarily indi-
cate active destruction [14–16], as severe T-cell infiltration
can be observed in either chronically rejecting or stable
allografts [17].
Recently, a new immunosuppressive agent, FTY720,
which is a synthetic analogue of a natural compound
from the fungus Isaria sinclairii has been developed [18].
Chemical structure and mode of action differ from con-
ventional immunosuppressants [19]. FTY720 prolonged
the survival of skin [20, 21], heart [22], liver [23, 24], kid-
ney [25–27], small bowel [28], pancreaticoduodenal [29],
and islet allografts [30], and prevented the development
of graft-versus-host immune responses [31] in rats and
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canines. Moreover, FTY720 even stopped ongoing acute
rejection, in heart and liver allografts [23, 32]. Combined
treatment with FTY720 and other immunosuppressive
agents, such as cyclosporine A [33] and tacrolimus (FK
506) [34, 35], exerted synergistic effects, and lead to per-
manent acceptance of allografts in some cases. Although
the exact mechanisms of the immunosuppressant have
not been fully elucidated, FTY720 induces apoptosis of
peripheral blood and graft infiltrating lymphocytes [23],
and accelerates the trafficking of circulating lymphocytes
to lymphoid tissues [36]. As a result, the number of infil-
trating lymphocytes in graft tissues is markedly reduced,
and their detrimental effects on acutely rejecting allo-
grafts are thus diminished.
Reports concerning effects of FTY720 on ongoing
chronic allograft nephropathy do not exist. Therefore,
in the present study, we initiated FTY720 treatment in a
well-established rat model of chronic allograft nephropa-
thy at week 12 after transplantation, when lymphocytic
influx into allografts becomes apparent [6, 7], and at week
20, when allograft fibrogenesis is ongoing [37].
METHODS
Animals
Naive inbred male Fisher (F344, RT1v1) and male
Lewis (RT1) rats (Charles River, Sulzfeld, Germany),
weighing 200 to 250 g, were kept under standard con-
ditions and fed with rat chow and water ad libitum. All
experiments were approved by a governmental commit-
tee on animal welfare and followed the “Principles of
Laboratory Animal Care” (NIH publication No. 86–23,
revised 1985).
Kidney transplantation
Under ketamine (Ketamin) (100 mg/kg intraperi-
toneally) (CP-Pharma, Burgdorf, Germany) and xy-
lacine (Rompun) (10 mg/kg intraperitoneally) (Bayer,
Leverkusen, Germany) anesthesia the left donor kid-
ney was removed, cooled, and positioned orthotopically
into the recipient. Donor and recipient renal artery,
vein, and ureter were anastomosed end-to-end with 10-0
Prolene sutures. No ureteral stent was used. To over-
come infectious complications rats received cephtriaxone
(Rocephin) (20 mg/kg/day, intramuscularly) (Hoffmann-
La Roche AG, Grenzach-Wyhlen, Germany) on the first
postoperative day. Animals were treated with low-dose
cyclosporine A (1.5 mg/kg/day subcutaneously) (Novartis
GmbH, Nu¨rnberg, Germany) over the first 10 days after
transplantation to overcome an initial episode of acute
rejection. The contralateral native kidney was removed
on the tenth postoperative day.
Experimental design
FTY720 (Novartis Pharmaceutical Industries, Basle,
Switzerland) was dissolved in physiologic saline, and ad-
ministered to recipients by oral gavage at 0.5 mg/kg.
Transplanted animals were assigned to four experimen-
tal groups (N =8/group) treated either with FTY720 from
week 12 to week 24 (FTY 12-24) or from week 20 to week
24 (FTY 20-24), or vehicle from week 12 to 24 (vehicle
12-24) or from week 20 to 24 (vehicle 20-24) after trans-
plantation. Kidney allografts were harvested 24 weeks
after transplantation.
Functional measurements
Every 4 weeks, body weight was measured and 24-hour
urine samples were collected using metabolic cages with
a urine cooling system. Quantitative urine protein was
nephelometrically determined. Serum and urine creati-
nine levels were measured and creatinine clearance was
calculated at the end of the study.
Histology
For histology, kidney tissues were fixed in 4% buffered
formalin, embedded in paraffin, and stained with either
hematoxylin and eosin or periodic acid-Schiff (PAS).
Glomerulosclerosis was defined as a collapse of capillar-
ies, adhesion of the obsolescent segment of Bowman’s
capsule, and entrapment of hyaline in the mesangium
[38]. All glomueruli in each section were counted and
the proportion of sclerosed to total glomeruli was ex-
pressed as percentage. Chronic allograft nephropathy in
terms of glomerulopathy, tubular atrophy, interstitial fi-
brosis, and vascular intimal proliferation were quantified
according to the Banff ′97 classification [38] and graded
as follows: 0, no signs of chronic allograft nephropathy;
grade 1, mild chronic allograft nephropathy with mild
fibrosis and tubular atrophy; grade 2, moderate chronic
allograft nephropathy with moderate fibrosis and tubular
atrophy; and grade 3, severe chronic allograft nephropa-
thy with severe fibrosis and tubular atrophy.
Immunohistochemistry
For immunohistology, cryostat sections (4 lm) were
fixed in acetone, air dried, and stained individually with
primary monoclonal mouse–derived antibodies against
monocytes/macrophages (ED1) and CD5+ T lympho-
cytes (OX19) (Serotec Camon Labor-Service GmbH,
Wiesbaden, Germany). After incubation with the pri-
mary antibody, sections were incubated with rabbit an-
timouse IgG and thereafter the alkaline phosphatase
antialkaline phosphatase (APAAP) complex (Dako
A/S, Hamburg, Germany). Cells staining positive were
counted and expressed as cells per field of view. At least
20 fields of view per section and per specimen were
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evaluated at 400× magnification by two independent ob-
servers in a blinded fashion.
TUNEL assay
Terminal deoxynucleotidyl transferase (dTd)-
mediated deoxyuridine triphosphate (dUTP) nick end-
labeling (TUNEL) assay was performed on frozen
sections fixed in paraformaldehyde 4% as described
elsewhere [39]. Briefly, sections were incubated with
Triton 0.1% and sodium citrate 0.1% at 4◦C. After
washing they were incubated with TUNEL solution.
Sections were washed with stop/wash buffer followed by
washing and incubation with a rabbit antidigoxygenin
antibody. Antibody binding was visualized using fast red
chromogen solution. Positive controls were treated with
DNase I and processed as described above. Negative
controls were incubated with phosphate-buffered saline
(PBS) instead of TUNEL solution. Sections were
counterstained with hematoxylin. All positive tubular
epithelial cells in each section were counted and related
to the number of fields of view per section.
RNase protection assay
Total RNA was extracted using Trizol reagent (Gibco,
Karlsruhe, Germany) according to the manufacturer’s
instructions. Intragraft mRNA expression specific for
interleukin (IL)-1a, IL-1b , IL-2, IL-5, IL-6, IL-10,
interferon-c (INF-c), tumor necrosis factor-a (TNF-a),
transforming growth factor-b (TGF-b1), platelet-derived
growth factor-B (PDGF-B), and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Riboquant Multi-
Probe template set) (Pharmingen, Becton Dickinson
GmbH, Hamburg, Germany) was determined by RNase
protection assay using the In vitro Transcription Kit and
RPA Kit (Pharmingen, Hamburg, Germany) as previ-
ously described [40]. Briefly, 32P-labeled antisense ri-
boprobes were synthesized with the use of T7 RNA
polymerase transcription in the presence of [a32P]-UTP.
Radiolabeled antisense riboprobes were then hybridized
with 10 lg of total RNA extracted from cultured cells
at 56◦C overnight. After hybridization, RNase A + T1
were added to digest unhybridized RNA and duplex
RNA hybrids were separated by electrophoresis on a 5%
polyacrylamide gel. Intensities of the protected bands
were quantified by a phosphorimaging analyzer (Fuji-
BAS 1500) (Du¨sseldorf, Germany) and the ratios of the
investigated genes to GAPDH (internal control) were
calculated.
Statistical analysis
Data are presented as mean ± SEM. Parametric
data were compared using one-way analysis of variance
(ANOVA), followed by multiple pairwise comparison ac-
cording to the Newman-Keuls test. Nonparametric data
were tested using the Kruskal-Wallis one-way analysis of
ranks. Discrete data were compared using chi-square test.
A P value of less than 0.05 was considered significant.
RESULTS
In comparison to controls, treatment with FTY720, ini-
tiated from either week 12 or week 20 after transplanta-
tion, significantly ameliorated signs of chronic allograft
nephropathy (Fig. 1A to D) in terms of glomerulosclero-
sis, interstitial fibrosis, tubular atrophy, and intimal prolif-
eration of graft arteries at the end of the follow-up period.
The percentage of sclerotic glomeruli was markedly
reduced in recipients treated with FTY720 from week
12 (20.0 ± 2.1% vs. 32.2 ± 2.5% in controls) (P < 0.01)
(Fig. 2). More interestingly, even FTY720 treatment from
week 20 reduced glomerulosclerosis (P < 0.05) (Fig. 2),
although to a lesser extent than in those treated from
week 12 (P < 0.05) (Fig. 2). Similarly, FTY720 resulted
in a reduced degree of glomerulopathy independent of
the treatment period. Most glomeruli in FTY720-treated
animals were of normal size with only minor hypercellu-
larity and patent capillary loops, while those in controls
revealed a more pronounced hypertrophy, with focal and
segmental proliferation.
Along with ameliorated glomerular injury, arteries ap-
peared relatively normal in FTY720-treated animals, with
only focal ballooning of endothelial cells or with vascu-
larization of the media (Fig. 1D). In addition, only minor,
nonspecific tubular changes were observed in grafts of
treated animals, and interstitial fibrosis was weak. By con-
trast, sections of allografts from controls demonstrated
more severe interstitial fibrosis, tubular atrophy, and in-
timal proliferation of the arteries. Some cortical arteries
contained mild intimal proliferation (<20% of vessel lu-
minal cross-section), while some had more than 50% of
luminal occlusion due to neointimal expansion (Fig. 1C).
Thus, animals from both treatment groups developed a
lower Banff score as compared to controls (P < 0.05)
(Fig. 3). Although animals treated with FTY720 from
week 12 tended to have less severe tubular and vascular
changes than those treated from week 20, the difference
did not reach statistical significance (Fig. 3).
Twenty weeks after transplantation, urinary protein ex-
cretion was lower in animals treated with FTY720 from
week 12 than in controls (23.8 ± 2.4 mg/dL/24 hours vs.
29.0 ± 4.8 mg/dL/24 hours (P > 0.05) (Fig. 4A). The differ-
ence became significant at week 24 (27.2 ± 3.7 mg/dL/24
hours vs. 42.5 ± 6.0 mg/dL/24 hours (P < 0.05) (Fig. 4A).
On the other hand, in animals treated with FTY720 from
week 20 urinary protein excretion at week 24 was only
slightly lower than in controls (31.9 ± 6.1 mg/dL/24 hours
vs. 41.0 ± 5.9 mg/dL/24 hours) (Fig. 4B). Serum creatinine
levels and creatinine clearance did not differ significantly
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Fig. 1. Microphotos of periodic acid-Schiff (PAS) staining (A to D), immunohistochemical staining with anti-CD5 monoclonal antibody (E and F),
and terminal deoxynucleotidyl transferase (dTd)-mediated deoxyuridine triphosphate (dUTP) nick end-labeling (TUNEL) staining (G and H) in
renal allografts harvested at 24 posttransplantation week. (A) FTY720 treatment resulted in minor changes. (B) Vehicle treatment resulted in severe
deterioration of graft tissue. (C) Normal artery after FTY720 treatment. (D) Intima proliferation after vehicle treatment. (E) Slight lymphocyte
infiltration in FTY720-treated animals. (F) Intense lymphocyte infiltration in vehicle-treated animals. (G) Diffused distribution of TUNEL-positive
infiltrates in FTY720-treated animals. (H) Limited amount of TUNEL-positive infiltrates in vehicle-treated animals.
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Fig. 2. Percentage of sclerotic glomeruli in renal allografts treated with
FTY720 (FTY) or vehicle (Veh) from 12 to 24 () or from 20 to 24 ()
post-transplantational weeks. ∗P < 0.05.
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Fig. 3. Banff classification of renal allografts demonstrating mild
(grade I, striated columns), moderate (grade II, ), and severe (grade
III, ) chronic allograft nephropathy. ∗P < 0.05 as compared to vehicle-
treated animals using chi-square test.
between the groups at the end of the follow-up (creati-
nine clearance 0.36 ± 0.05 mL/min/100 g body weight in
vehicle 12-20 vs. 0.37 ± 0.04 mL/min/100 g body weight
in FTY 12-24) (P > 0.05), and 0.37 ± 0.05 mL/min/100 g
body weight in vehicle 20-24 vs. 0.38 ± 0.06 mL/min/
100 g body weight in FTY 20-24) (P > 0.05).
To investigate whether FTY720 hindered the devel-
opment of chronic allograft nephropathy by reducing
mononuclear infiltrates in graft tissues, we determined
the intensity of T-cell and monocyte/macrophage infil-
tration with immunohistochemistry for CD5 and ED1,
respectively. FTY720 treatment reduced the intensity of
lymphocytic infiltration in renal allgrafts. While grafts of
controls were diffusely infiltrated by CD5-positive lym-
phocytes in interstitial areas, spreading from perivascular
to periglomerular regions and even surrounding Bow-
man’s capsules (Fig. 1E), grafts from FTY720-treated
animals had a relatively circumscript infiltration pat-
tern with a significantly lower number of T lymphocytes
(Fig. 5A) (P < 0.05) distributed primarily around vessels
(Fig. 1F), without any significant differences between an-
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Fig. 4. Changes in 24-hour urinary protein excretion during the course
of the experiment in animals treated with FTY720 () and vehicle ()
from 12-24 (A) and from 20-24 (B) weeks after transplantation. ∗P <
0.05 as compared to controls at the same time point.
imals treated for a longer period (week 12-24) or shorter
period (week 20-24) (Fig. 5A) (P > 0.05). On the other
hand, monocyte/macrophage infiltration in renal allo-
grafts was not influenced by FTY720 treatment, as ED1-
positive cell counts were similar in all groups (Fig. 5B).
In order to explore whether the reduced lymphocyte
infiltrates were accompanied by enhanced apoptosis, we
evaluated in situ DNA fragmentation in graft infiltrates
with the TUNEL assay. Apoptotic cells were identi-
fied basing on TUNEL staining and morphologic signs
of apoptosis, including chromatin condensation, detach-
ment of cytoplasm from the environment, and formation
of apoptotic bodies (Fig. 1G and H).
Apoptosis affected both the infiltrating leukocytes and
tubular epithelial cells. To no surprise, FTY720 treatment
increased the number of apoptotic graft infiltrating lym-
phocytes as compared to controls. While only ∼4% of
infiltrating lymphocytes were undergoing apoptosis in
vehicle-treated animals, FTY increased the percentage
to around 8% (P < 0.05) (Fig. 6). However, longer treat-
ment did not further enhance apoptosis in graft infiltrates,
as no significant differences were observed between an-
imals treated with FTY720 from week 12 or from week
20 (P > 0.05) (Fig. 6). On the other hand, we observed
no difference regarding the number of apoptotic tubular
epithelial cells between treatment groups and controls
(data not shown).
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Fig. 5. Immunohistochemical evaluation of CD5-positive (A) and
ED1-positive (B) cellular infiltration in renal allografts treated with
FTY720 (FTY) or vehicle (Veh) from 12-24 () and from 20-24 ()
posttransplantational weeks. ∗P < 0.05 vs. vehicle-treated animals.
0.00
2.00
4.00
6.00
8.00
10.00
12.00
Ap
op
to
tic
 in
te
rs
tit
ia
l c
el
ls,
 %
Veh FTY
*
*
Fig. 6. Percentage of apoptotic infiltrating cells in renal allografts
treated with FTY720 (FTY) or vehicle (Veh) from 12-24 () or from
20-24 () posttransplantational weeks. ∗P <0.05 as compared to vehicle-
treated animals.
We further investigated whether a reduction of lym-
phocytic infiltrates resulted in a decreased expression
of cytokines and growth factors. As shown in Figure 7,
FTY720 treatment from weeks 12 and 20 reduced IL-10
mRNA expression in allografts by twofold and 2.5-fold,
respectively, as compared to controls (P < 0.01). Addi-
tionally, TGF-b mRNA and PDGF-B mRNA expression
were significantly higher in controls than in FTY720-
treated animals (P < 0.05) (Fig. 7). No difference was
observed in IL-10, TGF-b , and PDGF mRNA expres-
sion between the two FTY720 treatment groups. Further-
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Fig. 7. RNase protection assay analysis of interleukin (IL)-10 (A),
transforming growth factor-b (TGF-b) (B), and platelet-derived growth
factor-B (PDGF-B) (C) mRNA expression in renal allografts treated
with FTY720 (FTY) or vehicle (Veh) from 12-24 () and from 20-24 ()
posttransplantational weeks. ∗P < 0.05 vs. vehicle-treated animals.
more, the expression of IL-1a, IL-1b , IL-2, IL-5, IL-6,
IFN-c, and TNF-a mRNA in renal grafts did not differ
between treatment and control groups (data not shown).
No differences in body weight were observed between
FTY720-treated animals and controls during the course
of the experiment (body weight at the time of harvesting
476 ± 28 g in vehicle12-24 vs. 463 ± 19 g in FTY 12-24
(P > 0.05) and 462 ± 21 g in vehicle 20-24 vs. 449 ± 23 g
in FTY 20-24 (P > 0.05). Likewise, mean arterial blood
pressure of FTY720-treated animals did not significantly
differ from controls [72.4 ± 6.2 mm Hg in vehicle 12-24
vs. 77.8 ± 6.8 in FTY 12-24 (P > 0.05) and 72.9 ± 4.7 in
vehicle 20-24 vs. 78.9 ± 6.6 in FTY 20-24 (P > 0.05).
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DISCUSSION
It has been well documented that lymphocytic infiltra-
tion is prominent in the interstitial areas of transplanted
kidneys during chronic allograft nephropathy [8, 9]. In
our previous studies, we observed that improved long-
term renal graft outcome was usually accompanied by
a reduction of infiltrating lymphocytes [41]. However,
whether the infiltration of T lymphocytes was cause or
consequence of chronic allograft nephropathy remained
unclear. In the present study, we demonstrated that re-
duction of lymphocytic infiltrates in rat renal allografts at
late stages after transplantation attenuated the progres-
sion of chronic allograft nephropathy.
Allograft biopsies of patients undergoing chronic re-
jection demonstrated lymphocytic infiltration of perivas-
cular as well as fibrotic interstitial areas, and even within
atophic tubules [4, 5, 42, 43]. In agreement, we observed
massive CD5-positive T cells infiltrating the interstitial ar-
eas of renal allografts in the control animals of our present
model. Presently, FTY720 emerges as the only immuno-
suppressant that exerts its effects on acute rejection by re-
ducing lymphocytic infiltration. Short-term application of
the drug markedly reduced lymphocytic infiltration in rat
cardiac, liver, skin, and renal allografts undergoing acute
rejection [20–26]. Combined treatment with FTY720 and
cyclosporine A in these models even depleted T-cell in-
filtrates and completely suppressed the intragraft expres-
sions of T-cell–associated cytokines [33–35]. Our present
results extended these findings to a model of chronic re-
jection, as late application of FTY720 initiated, either
when lymphocytic migration into allografts became ob-
vious (week 12), or when renal fibrosis was ongoing (week
20), significantly inhibited the number of infiltrating lym-
phocytes at late stages after transplantation.
Despite the presence of T lymphocytes in chronic re-
jection, it is still under controversy whether these cells are
responsible for chronic graft deterioration. In contrast to
acute rejection, T-cell–associated cytokines, such as IL-2,
IL-4, and IFN-c, were not up-regulated at late stages after
transplantation, and the expression of these cytokines did
not correlate to long-term allograft dysfunction [44, 45].
Additionally, intense lymphocytic infiltration could also
be observed in stable allografts long after transplantation
[17].
In this context, our present study aimed to give in-
sights into the contribution of infiltrating T lymphocytes
present late after renal transplantation to chronic allo-
graft nephropathy by diminishing the infiltration with
FTY720. Along with the marked reduction of infiltrating
lymphocytes, herein, long-term renal allograft function
assessed by 24-hour urinary protein excretion was im-
proved, and fibrogenesis of the allografts was remarkably
alleviated as a lower percentage of sclerotic glomeruli and
less severe interstitial fibrosis and arteriosclerosis were
observed in FTY720-treated recipients. In agreement, ev-
idence has been given in vitro that T cells isolated from
engrafted renal tissues from patients with chronic allo-
graft nephropathy were sensitized by peptides derived
from allogenic major histocompatibility complex [46] and
were highly response to phytohemagglutinin (PHA) and
Conconvalin A activation [47]. Collectively, these data
suggested that infiltrating T lymphocytes present at late
posttransplantational stages participate in chronic insults
to renal allografts.
More interestingly, although the same extent of lym-
phocytic infiltration was observed at the end of the follow-
up period in both FTY720 treatment groups, we found a
better long-term outcome in allograft function and patho-
logic changes in animals with FTY720 treatment before
allograft fibrogenesis was obvious (week 12). This prob-
ably indicated that not only infiltrating T lymphocytes
present during excessive allograft fibrogenesis (20 weeks
after transplantation), but also those present prior to ob-
vious renal fibrosis (from 12 to 20 posttransplantational
week) were involved in the ensuing graft damage, and re-
moving these infiltrates in both periods helped to further
reduce the pace of chronic allograft nephropathy.
The above findings suggested that T cells infiltrating
renal allografts late after transplantation were activated,
rather than in-activated or resting lymphocytes. Indeed,
following the reduction of lymphocytic infiltration, the
mRNA expression of IL-10, a Th2-related cytokine, was
markedly decreased despite the stable low expression of
Th1-type cytokines, such as IL-2 and IFN-c. These data
suggest that infiltrating lymphocytes present late after
transplantation were activated and were probably Th2
related. Th2-type cytokines have been associated with
the development of chronic rejection in allografts sur-
viving long-term [48]. In addition, IL-10 may promote
the proliferation of fibroblasts, and, thus, fibrogenesis and
artheriosclerosis in renal allografts [49]. Recently, it was
shown that supernatants of infiltrating lymphocytes iso-
lated from chronically rejecting renal allografts enhanced
PDGF-induced proliferation of vascular smooth muscle
cells [46]. Hence, we deduced that infiltrating lympho-
cytes at late posttransplantational stages might release
Th2-type cytokines, including IL-10, which contributed
to long-term renal allograft attrition. Late application of
FTY720 eliminated Th2 cytokines probably by reducing
lymphocytic infiltration, and thus limited the progression
of chronic allograft nephropathy.
In addition to reduced IL-10 levels, intragraft mRNA
expression of TGF-b and PDGF-B was also significantly
lower in FTY720-treated recipients. PDGF is likely to be
a critical event in fibroblast proliferation in vitro [50] and
in vivo [51] and has been associated with the development
of chronic allograft nephropathy [52]. The concomitant
reduction of intragraft expression of these growth factors
by FTY720 also lent support to the antifibrogenic effects
of the drug on renal allografts.
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Collectively, we deduced that late FTY720 treat-
ment protected renal allografts from chronic allograft
nephropathy by eliminating lymphocytic infiltrates in
graft tissues. Hence, the question arose what was re-
sponsible for the reduction of lymphocytic infiltrates in
our model. We further found that this effect was asso-
ciated with enhanced apoptosis of the graft infiltrates
in FTY720-treated animals. In agreement, FTY720 in-
duced apoptosis of infiltrating lymphocytes in renal and
liver allografts during acute rejection [23, 53]. This was
supported by previous in vitro results demonstrating a
number of apoptotic events in FTY-treated lymphocytes,
including genomic DNA fragmentation, chromatin con-
densation, and formation of apoptotic bodies [54]. Fur-
thermore, FTY720 led lymphocytes to programmed cell
death through intracellular activation of common sig-
nal pathways for apoptosis, including the activation of
the caspase cascade and protein kinases, by induction
of permeability transition to release cytochrome c from
mitochondria [55].
On the other hand, the binding capacity of lymphocytes
to allografts also determined the number of the infiltrates
in graft tissue. Our previous study suggested that lym-
phocyte binding in the allografts rises at 8 weeks, peaks
at 12 weeks and decreases at 16 weeks after transplan-
tation in this model. Such binding is determined partly
by the affinity of lymphocytes with graft tissues, which
is related to the expression of adhesive molecules in al-
lografts, and partly by the affinity of lymphocytes with
lymph nodes and Peyer’s patches due to the expression of
integrins on lymphocytes. It has been suggested that treat-
ment with FTY720 may increase the expression, affinity,
or avidity of a4-integrin (VLA-4) expression based upon
the effect of preincubation of treated lymphocytes with
an anti-VLA-4 monoclonal antibody to prevent the lym-
phodepletion effect of FTY720. If FTY720 alters VLA-4
expression, it would “home” lymphocytes to high en-
dothelial venules in lymph nodes and Peyer’s patches and,
thus, away from the allografts [56]. This may be respon-
sible for the reduction of lymphocyte infiltration due to
a decrease in lymphocytic influx into allografts. In this
context, a longer application of FTY720 may result in
further decrease in the intensity of lymphocytic infiltra-
tion. However, our results showed that the reduction of
lymphocyte infiltration was independent of the FTY720
treatment period, implying that infiltrate reduction may
mainly be a result of FTY720-induced apoptosis. Stud-
ies on aly/aly mice that lack lymph nodes and Peyer’s
patches support our findings by showing that FTY720
administration in these mice suppressed immune func-
tions in the same manner as in normal mice by inducing
lymphocyte apoptosis [57]. However, further studies are
needed to evaluate the alteration of lymphocyte traffick-
ing in chronic allograft nephropathy.
CONCLUSION
Our data suggest that lymphocytic infiltration at even
late stages after transplantation contribute to the devel-
opment of chronic allograft nephropathy. Therapies di-
rected toward the reduction of infiltrating lymphocytes,
such as FTY720-induced apoptosis, ameriolate long-term
renal allograft deterioration and thus reduce the pace of
chronic allograft nephropathy.
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